TriSalus Life Sciences (TLSI) Cash from Operations (2021 - 2026)

TriSalus Life Sciences' Cash from Operations history runs 6 years deep, the most recent figure standing at 6480000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 44.03% year-over-year to 6480000.0 in Q1 2026; TTM through Mar 2026 was 19993000.0, a 42.01% increase from a year earlier, with the FY2025 full-year figure at 18012000.0, up 55.9% from the prior year.
• Cash from Operations retreated to 6480000.0 in Q1 2026 per TLSI's latest filing, from 2484000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 425954.0 in Q1 2022 and bottomed at 22880298.0 in Q3 2022.
• The 5-year median for Cash from Operations is 8310000.0 (2022), against an average of 8719176.47.
• Across the five-year window, Cash from Operations plunged 6166.19% in 2022 and jumped 65.81% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 8310000.0 in 2022, then decreased by 10.43% to 9177000.0 in 2023, then surged by 37.81% to 5707000.0 in 2024, then surged by 56.47% to 2484000.0 in 2025, then sank by 160.87% to 6480000.0 in 2026.
• Per Business Quant, the three latest TLSI Cash from Operations figures stand at 6480000.0 (Q1 2026), 2484000.0 (Q4 2025), and 3709000.0 (Q3 2025).